West Pharmaceutical Services (WST) Non-Current Deffered Revenue (2019 - 2026)

West Pharmaceutical Services' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue rose 3.51% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $11.8 million (up 3.51% YoY), while the FY2025 annual figure was $13.5 million, down 12.34% from the prior year.
• Non-Current Deffered Revenue came in at $11.8 million for Q1 2026 at West Pharmaceutical Services, down from $13.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $26.3 million in Q1 2022 to a low of $11.4 million in Q1 2025.
• A 5-year average of $17.0 million and a median of $17.9 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue climbed 16.89% in 2022 and sank 38.71% in 2025, its largest moves.
• West Pharmaceutical Services' Non-Current Deffered Revenue stood at $19.1 million in 2022, then slipped by 2.62% to $18.6 million in 2023, then decreased by 17.2% to $15.4 million in 2024, then slipped by 12.34% to $13.5 million in 2025, then slipped by 12.59% to $11.8 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $11.8 million, $13.5 million, and $13.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison